title: Dual effect of docosahexaenoic acid (attenuation or amplification) on C22:0-, C24:0-, and C26:0-induced mitochondrial dysfunctions and oxidative stress on human neuronal SK-N-BE cells.
abstract: Increased levels of C22:0, C24:0 and C26:0 were found in cortical lesions of patients with Alzheimer's disease (AD). So, it was of interest to precise the cytotoxic effects of these fatty acids, and to determine whether docosahexaenoic acid (DHA), described to prevent AD, can attenuate their eventual side effects. Human neuronal SK-N-BE cells were cultured in the absence or presence of C22:0, C24:0 or C26:0 (0.1-20 µM) without or with DHA (50-150 µM). C22:0, C24:0 and C26:0 induce an inhibition of cell growth, a loss of Δψm, an overproduction of reactive oxygen species (ROS), a decrease of reduced glutathione, and a lipid peroxidation. DHA attenuates C22:0, C24:0 and C26:0 induced-mitochondrial dysfunctions and/or cell growth inhibition measured with MTT whatever the concentrations considered, whereas it can either decrease or amplify (especially at 150 µM) ROS overproduction. C22:0, C24:0 and C26:0 have neurotoxic activities, and depending on its concentration, DHA attenuates or not fatty acid-induced side effects.
authors: Dr. Gérard Lizard (Ph.D), Laboratoire BIO-peroxIL - EA 7270 / INSERM, Faculté des Sciences Gabriel, 6 Bd Gabriel, 21000 Dijon, France, E.Mail: gerard.lizard@u-bourgogne.fr ; Phone: +33 380 39 62 56; Fax: +33 380 39 62 50.
authors: A
authors: A
authors: Zarrouk
authors: T
authors: T
authors: Nury
authors: J M
authors: JM
authors: Riedinger
authors: O
authors: O
authors: Rouaud
authors: M
authors: M
authors: Hammami
authors: G
authors: G
authors: Lizard
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D004281:Docosahexaenoic Acids / Q000494:pharmacology*; D005227:Fatty Acids / Q000009:adverse effects* / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D018384:Oxidative Stress / Q000187:drug effects*; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D005227:Fatty Acids; D017382:Reactive Oxygen Species; D004281:Docosahexaenoic Acids; D005978:Glutathione
references: Acta Neuropathol. 2011 Sep;122(3):271-83
references: 21594711
references: J Nutr Health Aging. 2013 Mar;17(3):240-51
references: 23459977
references: Mol Neurobiol. 2012 Apr;45(2):366-78
references: 22415442
references: Mol Neurobiol. 2011 Apr;43(2):131-8
references: 21431475
references: Prostaglandins Leukot Essent Fatty Acids. 2013 Jan;88(1):105-14
references: 22727983
references: J Neurochem. 2014 May;129(3):516-26
references: 24345162
references: Traffic. 2011 Mar;12(3):252-9
references: 21083858
references: Neurochem Int. 2009 Dec;55(7):476-82
references: 19442696
references: J Alzheimers Dis. 2012;29(2):241-54
references: 22433776
references: Lancet Neurol. 2010 Jan;9(1):119-28
references: 20083042
references: Mol Aspects Med. 2009 Jun;30(3):153-70
references: 19248805
references: J Leukoc Biol. 1990 May;47(5):440-8
references: 2159514
references: Mol Aspects Med. 2009 Jun;30(3):171-9
references: 19248803
references: J Clin Invest. 2005 Oct;115(10 ):2774-83
references: 16151530
references: Oxid Med Cell Longev. 2012;2012:623257
references: 22919440
references: J Alzheimers Dis. 2009;18(4):935-52
references: 19749434
references: Eur Rev Med Pharmacol Sci. 2012 Nov;16(12):1651-64
references: 23161037
references: Chem Phys Lipids. 2011 Sep;164(6):457-68
references: 21703250
references: J Biol Chem. 2005 Dec 9;280(49):41057-68
references: 16204253
references: Cell Adh Migr. 2011 Jul-Aug;5(4):280-92
references: 21785276
references: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):320-30
references: 20624441
references: Cytometry. 1994 Apr 1;15(4):349-58
references: 8026225
references: Brain Dev. 2003 Oct;25(7):481-7
references: 13129591
references: J Immunol. 1983 Apr;130(4):1910-7
references: 6833755
references: Hum Immunol. 2012 Nov;73(11):1132-9
references: 22917540
references: J Biol Chem. 2008 Aug 8;283(32):21837-41
references: 18445586
references: Neurosci Lett. 2012 Oct 18;528(1):6-10
references: 22985512
references: Histochem Cell Biol. 2008 Apr;129(4):421-40
references: 18274771
references: Neuromolecular Med. 2011 Dec;13(4):223-50
references: 21901428
references: J Lipid Res. 2009 May;50(5):807-19
references: 19023138
references: Drug Metab Dispos. 2006 Apr;34(4):513-20
references: 16434543
references: J Alzheimers Dis. 2011;24 Suppl 2:61-73
references: 21422524
references: Nat Rev Neurol. 2013 Feb;9(2):106-18
references: 23296339
references: J Neurochem. 2007 Sep;102(6):1727-37
references: 17573819
references: Exp Brain Res. 2012 Apr;217(3-4):365-75
references: 22179528
references: Neurotoxicology. 2012 Mar;33(2):212-28
references: 22057157
references: Neurochem Int. 2010 Jan;56(2):318-28
references: 19913586
references: Mol Neurodegener. 2013 Feb 02;8:8
references: 23374228
references: Curr Alzheimer Res. 2010 Dec;7(8):656-64
references: 20678074
references: Neuroscience. 2012 Jun 28;213:1-18
references: 22521832